Country: United States
Language: English
Source: NLM (National Library of Medicine)
DIPHENOXYLATE HYDROCHLORIDE (UNII: W24OD7YW48) (DIPHENOXYLATE - UNII:73312P173G), ATROPINE SULFATE (UNII: 03J5ZE7KA5) (ATROPINE - UNII:7C0697DR9I)
Par Pharmaceutical, Inc.
DIPHENOXYLATE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE 2.5 mg
ORAL
PRESCRIPTION DRUG
Diphenoxylate Hydrochloride and Atropine Sulfate Tablets are effective as adjunctive therapy in the management of diarrhea. Diphenoxylate Hydrochloride and Atropine Sulfate tablets are contraindicated in patients with: Diphenoxylate Hydrochloride and Atropine Sulfate tablets are classified as a Schedule V controlled substance by federal regulation. Diphenoxylate hydrochloride is chemically related to the narcotic analgesic meperidine. In doses used for the treatment of diarrhea, whether acute or chronic, diphenoxylate has not produced addiction. Diphenoxylate hydrochloride is devoid of morphine-like subjective effects at therapeutic doses. At high doses it exhibits codeine-like subjective effects. The dose which produces antidiarrheal action is widely separated from the dose which causes central nervous system effects. The insolubility of diphenoxylate hydrochloride in commonly available aqueous media precludes intravenous self-administration. A dose of 100 to 300 mg/day, which is equivalent to 40 to 120 tabl
Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP 2.5 mg/0.025 mg are white, round, biconvex tablets, debossed ‘P’ over ‘771’ on one side and other side plain. NDC 49884-771-01 Bottles of 100 NDC 49884-771-10 Bottles of 1000 Store below 25°C (77°F). Dispense in a well-closed, light-resistant, child-resistant container. Manufactured by: PAR PHARMACEUTICAL, INC. Spring Valley, NY 10977 Revise 07/07 OS771-01-1-06
Abbreviated New Drug Application
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE- DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE TABLET PAR PHARMACEUTICAL, INC. ---------- DESCRIPTION Each diphenoxylate hydrochloride and atropine sulfate tablet for oral use contains: Diphenoxylate Hydrochloride ........................................... 2.5 mg Atropine Sulfate..................................................... 0.025 mg In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, microcrystalline cellulose, pregelatinized starch, and stearic acid. Diphenoxylate hydrochloride, an antidiarrheal, is ethyl 1-(3-cyano-3,3-diphenyl-propyl)-4- phenylisonipecotate monohydrochloride and has the following structural formula: Molecular formula C H N O •HCl M.W. = 489.05 Atropine sulfate, an anticholinergic, is 1αH,5αH-Tropan-3-α-ol(±)-tropate (ester), sulfate (2:1) (salt) monohydrate and has the following structural formula: Molecular formula (C H NO ) •H SO •H O M.W. = 694.83 A subtherapeutic amount of atropine sulfate is present to discourage deliberate overdosage. CLINICAL PHARMACOLOGY Diphenoxylate is rapidly and extensively metabolized in man by ester hydrolysis to diphenoxylic acid (difenoxine), which is biologically active and the major metabolite in the blood. After a 5 mg oral dose of carbon-14 labeled diphenoxylate hydrochloride in ethanolic solution was given to three healthy volunteers, an average of 14% of the drug plus its metabolites was excreted in the urine and 49% in the feces over a four-day period. Urinary excretion of the unmetabolized drug constituted less than 1% of the dose, and diphenoxylic acid plus its glucuronide conjugate constituted about 6% of the dose. In a sixteen-subject cross-over bioavailability study, a linear relationship in the dose range of 2.5 to 10 mg was found between the dose of diphenoxylate hydrochloride (given as Diphenoxylate HCl and Atropine Sulfate Oral Solution) and the peak plasma concentration, the area under the plasma concentration Read the complete document